Introduction
The role of peripheral immune cells in MS pathology
Autoimmune response
Chronic inflammatory response
Demyelination reaction
The mitochondrial of peripheral immune cells in MS
Mitochondria in MS T cells
Mitochondria in MS CD4+ T cells
Mitochondria in MS CD8+ T cells
Mechanism of mitochondrial and metabolic dysfunction | T cell functions | References |
---|---|---|
Bcl2, OPA1, PHB2, SIRT3, OMA1 and ATG5 regulate mitochondria-mediated death | Regulate apoptosis of T cells | |
Increase aldolase, HK-1, ENO1, GLUT1, DLAT and DLST, glycolysis and mitochondrial respiration activity via IFN beta treatment | Restore T cell metabolic remodeling | [77] |
Increase oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) through enhancing complex III activity of the ETC after teriflunomide treatment | Prevent the proliferation of T cells | [78] |
Reduction in the superoxide dismutase (SOD) and glutathione peroxidase (GPX), as well as an increase in the protein Hsp70 caused by oxidative stress, lead to increase GLUT1 and lactate | Regulate CD4+ T cell metabolic reprogramming | [75] |
ROS-driven activation of TGF-β signaling in CD4+ T cells | Encourage the differentiation of Th17 cells | [80] |
MitoTEMPO inhibits ROS in Treg | Decline Th1 and Th17 cells differentiation | [81] |
Oleic acid enhances fatty acid β-oxidation of Treg | Enhance inhibition of tissue-resident Treg | [86] |
Upregulated mTOR activity increases acetyl-CoA levels and glucose oxidation by pentanoate | Increase IL-10 secretion and suppress IL-17A production in CD4+ T cells | |
Phospholipids (PLs) suppress phosphorylation of Bim and Bad molecules | Inhibit the activation and promotion apoptosis of autoreactive CD4+ T cells | [90] |
Acetyl-CoA carboxylase 1 (ACC1) promotes de novo fatty acid production and the glycolytic-lipogenic pathway | Increase IFN-γ+ Th17 cells number and decrease FOXP3+ Tregs number in the spinal cord | [91] |
Atorvastatin induces p-STAT6, inhibits p-STAT4 expression and cholesterol synthesis | Promote Th2 cells differentiation, inhibit Th1 and Th 17 cells differentiation | [92] |
Inhibit PFKFB3-HIF1α activation | Decline Th17 cells differentiation | [94] |
Decrease transcription factor TF-like (BATF) expression and upregulate ATP-linked oxidative phosphorylation (OXPHOS) | Promote Th17 cells differentiation and increase the chromatin accessibility | |
Linezolid disrupts the integrity of the ETC by inhibiting mitochondrial elongation factor G1 (mEF-G1) and the ratio of NAD+/NADH | Promote Th17 and Th1 cells differentiation | [97] |
Pik3c3-deficient CD4+ T downregulation of ECAR and OCR | Inhibit Th1 cells differentiation | [98] |
Nur77 knock-out enhances OCR and EACR | Promote Th1 and Th17 cells differentiation | [99] |
2-DG treatment in CD8+ T cells reduces CD69 and CD25 | Decrease CD8+ T cells activation and TNF α production | [103] |
DMF reduces intracellular GSH, CytC and induces ROS, mitochondrial membrane potential (MMP), OCR and caspase-mediated apoptosis | Increase apoptosis of CD4+ T cells and CD8+ T cells | [104] |
DMF increases ROS in Tc17 cells through PI3K-AKT-T-BET and IL-2-STAT5 signaling pathways | Decrease IL-17 production in Tc17 cells and inhibit type I or II histone deacetylases (HDACs) histone acetylation on the Il17 locus | [105] |
Mitochondria in MS B cells
Mechanism of mitochondrial and metabolic dysfunction | B cell functions | References |
---|---|---|
Downregulated high-density lipoprotein (HDL) production by obeticholic acid (OCA) treatment | Reduce the number of B cells and B cell exhaustion | [111] |
Upregulated glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and trisaccharide phosphoisomerase (TPI) in the CSF | Drive B cell clonal expansion | [112] |
BTKi treatment limits OCR in B cells partially through PI3K/AKT/mTOR pathway | Attenuate B cell activation and antigen-presenting function | [113] |
Mitochondria in MS monocytes
Mechanism of mitochondrial and metabolic dysfunction | Monocytes functions | References |
---|---|---|
The inhibitor 6877002 decreases ROS production of monocytes through CD40-TRAF6 pathway | Reduce pro-inflammatory cytokines (TNF, IL-6) production and trans-endothelial migration ability | [115] |
2-DG treatment reduces glucose uptake, lactate secretion and ECAR in monocytes, which was correlated with a decrease in the expression of Glut1, HK-2, TPI, PKM, LDHA, and MCT-1 | Switch to an anti-inflammatory phenotype and 2-DG treated monocytes attenuate the severity of experimental autoimmune encephalomyelitis (EAE) | [114] |
DMF treatment increases ROS production in monocytes, which was correlated with genetic variation and CpG methylation in monocytic NOX3 | Increase the numbers of monocytes | [120] |
IFN-beta treatment alters mitochondrial dysfunction pathway and mitochondrial ETC-related genes | Decrease monocytic ROS production |
Mitochondria in MS Mϕ
Mechanism of mitochondrial and metabolic dysfunction | Mϕ functions | References |
---|---|---|
DMF blocks the glycolysis process and ROS production by decreasing extracellular signal-regulated kinase (ERK) phosphorylation | Inhibit antigen-presenting function in Mϕ and switch to M2 phenotype | |
FhHDM-1 upregulates oxidative phosphorylation (OXPHOS) and decreases glycolysis | Inhibit Mϕ activation and pro-inflammatory cytokines expression | |
P47phox mediated ROS generation | Accumulate in infiltrating Mϕ and involved in demyelination | |
Fibrin upregulates ROS production through enhancing oxidative stress genes (Ncf2, Sod2, Nox2) and p47phox | Promote activation of Mϕ and demyelination and axonal damage | |
Deleting LDHA or MCT4 reduces lactate production | Inhibit pro-inflammatory Mϕ activity | [118] |
Glycolysis upregulated in MHC-II+ Mϕ was associated with glucose transporters (GLUTs) and MCT-1 | Promote MHC-II+ Mϕ activity in demyelination | [138] |
Mitochondria in MS neutrophils
Mechanism of mitochondrial and metabolic dysfunction | Neutrophils functions | References |
---|---|---|
Knock-out CXCR2 reduces ROS production through inhibiting Ncf1 and IL-1β production | Reduce the inflammatory cytokines | [143] |
Deficiency of Socs3 elevates ROS through activating G-CSF/STAT3 signaling | Enhance neutrophil activation | [144] |
Mitochondria in MS DCs
Mechanism of mitochondrial and metabolic dysfunction | DC functions | References |
---|---|---|
Sirt6 inhibition potentially mediates metabolic pathways | Reduce migration and activation of DCs | |
Knock-out NOX2 in DCs can inhibit T cell-mediated autoimmune neuroinflammation through LC3-associated phagocytosis (LAP) | Inhibit myelin peptide presentation of DCs | [154] |
Increased HIF-1α-NDUFA4L2 signaling inhibits X-box binding protein 1 (XBP1) and leads to downregulating OCR and ROS | Promote pro-inflammatory activities and activation of DCs | [155] |
Tgfbr2 insufficiency in moDCs upregulates ROS production via NOX2 | Secret more IL-12 in moDCs which induces Th1 polarization and chronic inflammatory demyelination | [156] |
DMF partly though GSH-HO-1 pathway regulating oxidative stress | Decrease maturation and antigen‐presenting capacity of pro-inflammatory DCs |
Conclusion
DMT drugs | Immune cell type | Mechanism of mitochondrial and metabolic dysfunction | References |
---|---|---|---|
Interferon beta | T cell | Reverse the decreased glycolysis and mitochondrial respiration activity by upregulating the expression of aldolase, HK-1, ENO1, GLUT1, DLAT and DLST | [77] |
DC | Suppress the differentiation of Th17 cells and induces IL-10 secretion via activated STAT1 and STAT3 | [151] | |
Monocyte | Alter monocytic ROS production and mitochondrial ETC-related genes | ||
Dimethyl fumarate (DMF) | CD4 or CD8 | Increase caspase-mediated apoptosis through CytC, reduce intracellular GSH, increase MMP, ROS levels and mitochondrial OCR | [104] |
Tc17 | Upregulate ROS in Tc17 cells through PI3K-AKT-T-BET and IL-2-STAT5 signaling pathways | [105] | |
Monocyte | Upregulate monocytic ROS production as a result of genetically sustained low level of the promotor methylation of NOX3 | [120] | |
Mϕ | Inhibit glycolysis process and ROS production through decreasing ERK phosphorylation | [124] | |
DC | Regulate oxidative stress potentially through modulation GSH-HO-1 pathway | ||
Teriflunomide | T cell | Enhance OCR and EACR by boosting complex III activity in the ETC | [78] |